Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke? Discordance between randomised controlled trials and observational studies
AJ Scheen - Diabetes & Metabolism, 2023 - Elsevier
Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular
complication has been less carefully investigated than the risk of cardiovascular mortality …
complication has been less carefully investigated than the risk of cardiovascular mortality …
A Comprehensive Review of Membrane Transporters and MicroRNA Regulation in Alzheimer's Disease
Alzheimer's disease (AD) is a distressing neurodegenerative condition characterized by the
accumulation of amyloid-beta (Aβ) plaques and tau tangles within the brain. The …
accumulation of amyloid-beta (Aβ) plaques and tau tangles within the brain. The …
The neuronal and non-neuronal pathways of sodium-glucose cotransporter-2 inhibitor on body weight-loss and insulin resistance
M Dong, H Chen, S Wen, Y Yuan, L Yang… - Diabetes, Metabolic …, 2023 - Taylor & Francis
With the emergence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the treatment of
type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin …
type 2 diabetes mellitus (T2DM) has achieved a new milestone, of which the insulin …
[HTML][HTML] Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour …
G Floresta, D Arillotta, V Catalani… - Scientia …, 2024 - mdpi.com
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable
attention as a therapeutic agent for type 2 diabetes mellitus and obesity. Despite its clinical …
attention as a therapeutic agent for type 2 diabetes mellitus and obesity. Despite its clinical …
[HTML][HTML] Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
C Hölscher - Neuropharmacology, 2024 - Elsevier
Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …
GLP-1 in the Hypothalamic Paraventricular Nucleus Promotes Sympathetic Activation and Hypertension
XY Xu, JX Wang, JL Chen, M Dai… - Journal of …, 2024 - Soc Neuroscience
Glucagon-like peptide-1 (GLP-1) and its analogs are widely used for diabetes treatment. The
paraventricular nucleus (PVN) is crucial for regulating cardiovascular activity. This study …
paraventricular nucleus (PVN) is crucial for regulating cardiovascular activity. This study …
[HTML][HTML] The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
E Vercalsteren, D Karampatsi, C Buizza… - Cardiovascular …, 2024 - Springer
Abstract Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities.
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …
Currently, there are no therapies targeting this important clinical problem. Sodium-glucose …
New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer's disease
Alzheimer's disease (AD) is a chronic neurodegenerative disorder affecting a major class of
silver citizens. The disorder shares a mutual relationship on account of its cellular and …
silver citizens. The disorder shares a mutual relationship on account of its cellular and …
[HTML][HTML] Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed …
D Arillotta, G Floresta, GD Papanti Pelletier, A Guirguis… - Brain Sciences, 2024 - mdpi.com
Glucagon-like peptide-1 (GLP-1) is involved in a range of central and peripheral pathways
related to appetitive behavior. Hence, this study explored the effects of glucagon-like peptide …
related to appetitive behavior. Hence, this study explored the effects of glucagon-like peptide …
[HTML][HTML] What Is Food Noise? A Conceptual Model of Food Cue Reactivity
As GLP-1 receptor agonists, like semaglutide, emerge as effective treatments for weight
management, anecdotal reports from patients and clinicians alike point to a reduction in …
management, anecdotal reports from patients and clinicians alike point to a reduction in …